Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from September 30, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on December 29, 2025 — +36.4% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$78.19 Published $86.83 Target $106.62 Window close $107.59 Peak
$75.21 – $78.65Entry zone — fair-value band
$78.19Published — price the day we called it
$86.83Target — the price the thesis aimed for
$107.59Peak — highest point inside the window, not a realized return
$106.62Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 1 day.

At window close
+36.4%
realized, from the publication price to the last close inside the window
Peak gain
+37.6%
peak, from the publication price — not a realized return
S&P 500, same window
+3.6%
SPY over the identical days, dividend-adjusted
Window close
$106.62
last close inside the window, ended December 29, 2025
Peak price
$107.59
peak on December 29, 2025 — not a realized return
Days to target
1

The thesis — published September 30, 2025

Predicted growth
+12%
over the measurement window
Target price
$86.83
the price the thesis aimed for
Entry zone
$75.21 – $78.65
the fair-value band we waited for
Price at publication
$78.19
published September 30, 2025
Confidence
73%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck looks like a steady, lower-drama stock that has dropped more than usual and could rebound. A late-September study showed its WINREVAIR drug cut disease worsening by 76 percent, boosting confidence in its research. A new AI partner may help Merck find medicines faster. Even if a common price signal is weak, real progress and a strong lineup could pull the stock back toward its recent average this quarter.

Primary drivers

  • Late-September WINREVAIR study cut disease worsening by 76 percent
  • AI-focused partner aims to speed up how Merck discovers new drugs
  • Price looks washed out, offering a possible short-term bounce entry
  • Stable earnings make the stock more resilient during tough markets

How it played out

MRK: target reached in 1 day

Lyra published MRK at 78.19 on 2025-09-30 with 12% expected growth and an 86.83 target. The thesis pointed to a late-September WINREVAIR study that cut disease worsening by 76 percent, a drug-discovery partnership tied to artificial intelligence, a washed-out price setup, and stable earnings.

Inside the window, MRK reached the 86.83 target after 1 day. The stock later rose to a 107.59 peak on 2025-12-29, with a 37.6% peak gain. It ended at 106.62. The thesis played out and then went well past the target.

What happened during the window

On 2025-10-30, Merck reported third-quarter sales of $17.28 billion and adjusted earnings per share of $2.58. The same report said WINREVAIR sales rose 141% year over year to $360 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals